← Leaderboards
Stuart A Chalew
Tulane University Of Louisiana
$446,286
Attributed
$446,286
Total exposure
8
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $276K · FY2005–20$500K$375K$250K$125K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
Funding mix
By agency
NIH$446,286 · 8
By mechanism
R21$433,368 · 1
M01$12,918 · 7
Top collaborators
No co-investigators on record.
Most similar at Tulane University Of Louisiana
Same institution · by research overlap
- Russell Barrett Van Dyke$24,377,705
- Richard A Oberhelman$11,866,170
- Samir S El-Dahr$10,425,237
- Lu Qi$19,868,722
- Michael S Scheeringa$3,663,636
Others in their field
Top investigators on “Clinical Research”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,040,569,537
- Leonard Freedman · Leidos Biomedical Research, Inc.$975,089,882
- Lawrence Corey · Fred Hutchinson Cancer Center$739,766,552
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Jeffrey P Krischer · University Of South Florida$611,867,176
- Barton F Haynes · Duke University$538,862,577
Research focus
Clinical ResearchHuman SubjectInsulin Dependent Diabetes MellitusHuman Therapy EvaluationInsulinClinical TrialsClinical Trial Phase IDiabetes Mellitus TherapyPathologic ProcessDisease /Disorder Prevention /ControlFamilyDiabetes MellitusBehavioralChildhood DiabetesComplicationChildhoodAreaAdherenceCustomCognitive DeficitsChildClinical TreatmentCognitive DevelopmentBlood Glucose Regulation
Grant awards (12)
Defining the Role of Management Factors in Outcome Disparity in Pediatric T1D$157,330
R21 · FY2020 · DK · contact PI
Defining the Role of Management Factors in Outcome Disparity in Pediatric T1D$276,038
R21 · FY2019 · DK · contact PI
GROWTH HORMONE ON INTRAMYOCELLULAR LIPID CONTENT IN CHILDREN WITH PRADER-WILLI$148
M01 · FY2005 · RR
Diabetes Prevention Trial - Type I Diabetes (DPT-1)$1,060
M01 · FY2004 · RR
Health Outcomes of Weight-Loss in Pediatric Type 2 DM$530
M01 · FY2004 · RR
EFFECTS OF CYTOKINES ON IMMUNE MEDIATED TYPE 1 DIABETES$0
M01 · FY2001 · RR
DIABETES PREVENTION TRIAL--TYPE 1 DIABETES (DPT-1)$0
M01 · FY2001 · RR
FEASIBILITY OF ORAL INSULIN THERAPY TO DELAY BETA CELL DESTRUCTION IN$0
M01 · FY2001 · RR
DIABETES PREVENTION IN OBESE AFRICAN AMERICAN CHILDREN$11,180
M01 · FY2000 · RR
DIABETES PREVENTION TRIAL--TYPE 1 DIABETES (DPT-1)$0
M01 · FY2000 · RR
EFFECTS OF CYTOKINES ON IMMUNE MEDIATED TYPE 1 DIABETES$0
M01 · FY2000 · RR
FEASIBILITY OF ORAL INSULIN THERAPY TO DELAY BETA CELL DESTRUCTION IN$0
M01 · FY2000 · RR